Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation

James T. Lane, David E. Odegaard, Claire E. Haire, Dean S. Collier, Lucile E. Wrenshall, R. Brian Stevens

Research output: Contribution to journalLetterpeer-review

Abstract

New-onset diabetes after transplantation (NODAT) remains a frequent and serious complication after kidney transplantation. We previously reported NODAT in our postkidney transplant population at a frequency of more than 50%, using the definition established by the 2003 International Guidelines. This high rate of posttransplant diabetes has serious negative consequences for future cardiovascular risk and survival after kidney transplant.

Original languageEnglish
Pages (from-to)e56-e57
JournalTransplantation
Volume92
Issue number10
DOIs
StatePublished - Nov 27 2011

ASJC Scopus Subject Areas

  • Transplantation

Disciplines

  • Medical Cell Biology
  • Medical Neurobiology
  • Medical Physiology
  • Medical Sciences
  • Medicine and Health Sciences
  • Neurosciences
  • Physiological Processes

Cite this